The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a multiple-center, prospective, open-label, positive drug controlled, randomized, clinical study to evaluate the safety and efficacy of Telitacicept in the treatment of primary membranous nephropathy.